Boston Scientific Acquires SVG Embolic Protection At Reduced Cost
This article was originally published in The Gray Sheet
Rubicon Medical will forego a higher payment for its embolic filter technology than originally expected from Boston Scientific, opting instead for immediate cash flow to support commercialization
You may also be interested in...
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.